Novo Nordisk drags competitor to court over Saxenda copies

Novo Nordisk has summoned Orbicular Pharmaceutical Technologies before a court in Delaware in the US to block the launch of a generic copy of its obesity drug, Saxenda, Bloomberg News reports.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk and Leo Pharma seek permission to use oil
For subscribers